Rising Biosciences Anticipates Products on MMJ
Dispensary Shelves in Late September 2018
RBII to Contract with Producers/Processors in MMJ
States to License and Market Cannophen, THC Products
SANDUSKY, OH -- June 11,
2018 -- InvestorsHub NewsWire -- Rising Biosciences,
Inc.
(OTC:RBII)
("RBII" "the Company"), a research and development company focusing
on oral and topical pharmaceuticals with strict standards set
forward by the pharmaceutical compounding industry, is pleased to
announce that it is
currently working with producers and processors in California,
Arizona and Ohio to produce its products under licensing agreements
with a target for end of September 2018 for the Company's first
products to hit dispensary shelves.
Rising Biosciences is also
pleased to announce that FINRA has approved its name
and ticker change and the Company is currently recognized by OTC
Markets and otherwise as Rising
Biosciences, Inc. under ticker
RBII.
As well, the Board
has voted to move forward with steps to file a registration with
the SEC to become a fully reporting company. We are currently
identifying legal counsel and auditing firm toward QB while growing
operations to meet listing qualifications for one of the major
exchanges. The Company is also interviewing a digital marketing
firm to assist with public relations and marketing of its
revolutionary product line.
CEO Robert Weber announces
that Rising Biosciences is now in the final stages of FDA testing
of its TSW Pain Cream products and have entered a contract
with Reed Tech Life
Sciences, a Medical Device,
Prescription Drug OTC and Biologics Regulatory Professional
Firm.
"They will be
handling our FDA drug listing requirements, and obtaining our NDC,
which stands for 'national drug code' for our pain cream products.
Having this NDC will allow us to have physicians write
prescriptions for the pain creams. In line with president trumps
initiative to stop opiate abuse, also making it payable by
Medicaid, Medicare and private insurance companies. We will also be
offering a version of the creams for the retail market as
well."
Weber adds, "Also,
our new stem cell cream has now gone into production, and will be
available for sale by the end of this quarter. This product will
first be available on Amazon. Our clinical strength peptide
complex exceeded our expectations
on Amazon, and we expect to be similarly pleased with customer
reception of our stem cell cream."
$RSII on Twitter for LIVE
company updates! www.twitter.com/risingindiausa
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act
of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934,
and are subject to the safe harbor created by those rules. All
statements, other than statements of fact, included in this
release, including, without limitation, statements regarding
potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward- looking statements to reflect events or circumstances
after the date of this release.
CONTACT
INFO: For Investor
Inquiries:IR@risingbiosciences.com
